BACKGROUND: The association between nuclear factor I/B (NFIB) gene and triple negative breast cancer has been previously suggested. METHODS: We investigated the relationship between NFIB mRNA and protein expression and molecular subtypes of breast cancer as well as the effect of NFIB silencing on the proliferation and apoptosis of breast cancer cells. Also, the clinical importance of NFIB expression was investigated in 163 breast cancer patients. RESULTS: By using 20 frozen human breast cancer tissues and various breast cancer cell lines, we observed a significant high level of NFIB mRNA level in triple negative breast cancer. NFIB protein was upregulated in ER negative breast cancer tissues but the expression level was similar between HER2 subtype and triple negative subtype. The clinical significance of NFIB was further examined in a tissue microarray from 163 invasive breast cancer patients, and the immunohistochemistry results showed a significant association between NFIB expression and nuclear grade, ER, and HER2 expression status. NFIB positive tumors were more likely to have high nuclear grade, ER negativity and HER2 over-expression. HCC1954 cells transfected with siRNA against NFIB showed a significant reduction in cell proliferation and increase in apoptotic signaling pathway. CONCLUSIONS: Our results show a potential role of NFIB as a novel target in ER negative breast cancers.
BACKGROUND: The association between nuclear factor I/B (NFIB) gene and triple negative breast cancer has been previously suggested. METHODS: We investigated the relationship between NFIB mRNA and protein expression and molecular subtypes of breast cancer as well as the effect of NFIB silencing on the proliferation and apoptosis of breast cancer cells. Also, the clinical importance of NFIB expression was investigated in 163 breast cancerpatients. RESULTS: By using 20 frozen humanbreast cancer tissues and various breast cancer cell lines, we observed a significant high level of NFIB mRNA level in triple negative breast cancer. NFIB protein was upregulated in ER negative breast cancer tissues but the expression level was similar between HER2 subtype and triple negative subtype. The clinical significance of NFIB was further examined in a tissue microarray from 163 invasive breast cancerpatients, and the immunohistochemistry results showed a significant association between NFIB expression and nuclear grade, ER, and HER2 expression status. NFIB positive tumors were more likely to have high nuclear grade, ER negativity and HER2 over-expression. HCC1954 cells transfected with siRNA against NFIB showed a significant reduction in cell proliferation and increase in apoptotic signaling pathway. CONCLUSIONS: Our results show a potential role of NFIB as a novel target in ER negative breast cancers.
Authors: Yoshitsugu Mitani; Jie Li; Pulivarthi H Rao; Yi-Jue Zhao; Diana Bell; Scott M Lippman; Randal S Weber; Carlos Caulin; Adel K El-Naggar Journal: Clin Cancer Res Date: 2010-08-11 Impact factor: 12.531
Authors: Henrike E Karim-Kos; Esther de Vries; Isabelle Soerjomataram; Valery Lemmens; Sabine Siesling; Jan Willem W Coebergh Journal: Eur J Cancer Date: 2008-02-14 Impact factor: 9.162
Authors: Marta Persson; Ywonne Andrén; Joachim Mark; Hugo M Horlings; Fredrik Persson; Göran Stenman Journal: Proc Natl Acad Sci U S A Date: 2009-10-19 Impact factor: 11.205
Authors: Thomas M Campbell; Mauro A A Castro; Kelin Gonçalves de Oliveira; Bruce A J Ponder; Kerstin B Meyer Journal: Cancer Res Date: 2017-11-27 Impact factor: 12.701
Authors: Cheng-Ying Ho; Eli Bar; Caterina Giannini; Luigi Marchionni; Matthias A Karajannis; David Zagzag; David H Gutmann; Charles G Eberhart; Fausto J Rodriguez Journal: Neuro Oncol Date: 2012-11-15 Impact factor: 12.300
Authors: Eleni M Rettig; C Conover Talbot; Mark Sausen; Sian Jones; Justin A Bishop; Laura D Wood; Collin Tokheim; Noushin Niknafs; Rachel Karchin; Elana J Fertig; Sarah J Wheelan; Luigi Marchionni; Michael Considine; Shizhang Ling; Carole Fakhry; Nickolas Papadopoulos; Kenneth W Kinzler; Bert Vogelstein; Patrick K Ha; Nishant Agrawal Journal: Cancer Prev Res (Phila) Date: 2016-02-09
Authors: Lisa Mirabello; Roelof Koster; Branden S Moriarity; Logan G Spector; Paul S Meltzer; Joy Gary; Mitchell J Machiela; Nathan Pankratz; Orestis A Panagiotou; David Largaespada; Zhaoming Wang; Julie M Gastier-Foster; Richard Gorlick; Chand Khanna; Silvia Regina Caminada de Toledo; Antonio S Petrilli; Ana Patiño-Garcia; Luis Sierrasesúmaga; Fernando Lecanda; Irene L Andrulis; Jay S Wunder; Nalan Gokgoz; Massimo Serra; Claudia Hattinger; Piero Picci; Katia Scotlandi; Adrienne M Flanagan; Roberto Tirabosco; Maria Fernanda Amary; Dina Halai; Mandy L Ballinger; David M Thomas; Sean Davis; Donald A Barkauskas; Neyssa Marina; Lee Helman; George M Otto; Kelsie L Becklin; Natalie K Wolf; Madison T Weg; Margaret Tucker; Sholom Wacholder; Joseph F Fraumeni; Neil E Caporaso; Joseph F Boland; Belynda D Hicks; Aurelie Vogt; Laurie Burdett; Meredith Yeager; Robert N Hoover; Stephen J Chanock; Sharon A Savage Journal: Cancer Discov Date: 2015-06-17 Impact factor: 39.397